Lupin Pharmaceuticals’ smooth-run in Japan; all eyes on biosimilars growth

which would come from biosimilars and it expects nearly 50 per cent of its Japan sales to come from the speciality business. Lupin’s Japan story assumes significance as it held on to the highly regulated market, when most of its Indian peers quit.
( read original story …)


Related Post

AP Interview: Japan’s emoji creator saw nuan...
views 211
TOKYO — The Japanese creator of the first emoji wa...
Earthquake of 5.6 magnitude hits Japan, 5 injured
views 112
A 5.6-magnitude earthquake hit western Japan early...
Nikkei slips as U.S. turmoil unnerves investors, T...
views 214
TOKYO May 19 Japan's Nikkei share average dipped o...
Japan’s Hanyu sets Olympic record in short p...
views 155
Oh yeah, there he was, at center ice, bowing to a ...
Nagoya-Đà Nẵng flight set to launch soon
views 22
ĐÀ NẴNG — The central city of Đà Nẵng is planning ...
Tokyo, Japan (Autumn 2017) – Part 1
views 206
This trip to Tokyo will be broken down into 2 part...
Deutsche Bank USD/JPY Forecast To Rise To 120-125
views 307
In the latest research report from Deutsche Bank, ...
Tokyo jeweler offers gold Darth Vader mask for $1....
views 247
Star Wars fans might consider it a golden opportun...
Bank of Japan : Accounts (June 10)
views 59
Pecuniary trusts (index-linked exchange-traded fun...
Japan Display to raise stake in OLED display maker...
views 248
Japan Display Inc (6740.T) will raise its stake in...